Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 9Terminated 3Recruiting 3Active not recruiting 3Withdrawn 2Unknown 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Recurrence 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × OTHER × midostaurin × Clear all
NCT04982354 2024-10-01

Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

Baptist Health South Florida

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03207334 2018-10-22

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

University of Florida

Phase 2 Withdrawn
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡